Skip to main content

Table 4 The league table for ORR estimates interventions according to their relative effects in first part network analysis

From: Second-line treatment strategy for urothelial cancer patients who progress or are unfit for cisplatin therapy: a network meta-analysis

Apatorsen+Taxane (64.9%)a
0.37 (− 1.08,1.83)Icrucumab+Taxane (46.8%)     
1.66 (−0.02,3.33)1.29 (− 0.44,3.01)Pazopanib (6%)    
−0.31 (−1.40,0.77)− 0.69 (− 1.72,0.35)−1.97 (− 3.40,-0.54)bRamucirumab+Taxane (82.4%)   
0.44 (− 0.54,1.43)0.07 (−1.00,1.14)−1.22 (− 2.57,0.14)0.76 (0.30,1.21)Taxane (41.5%)  
0.93 (−0.60,2.46)0.55 (−1.03,2.14)−0.73 (−2.52,1.06)1.24 (− 0.01,2.50)0.49 (− 0.68,1.65)Vandetanib+Taxane (24%) 
− 0.61 (− 2.44,1.22)−0.98 (− 2.86,0.90)−2.27 (−4.32,-0.21)−0.29 (− 1.91,1.32)−1.05 (− 2.59,0.50)−1.54 (− 3.47,0.40)Vinflunine (84.4%)
  1. ORR Objective response rate
  2. aThe SUCRA probabilities are performed in brackets
  3. bBold font means significant different